What is Zacks Research's Forecast for Biogen Q2 Earnings?

Biogen Inc. (NASDAQ:BIIB - Free Report) - Equities research analysts at Zacks Research decreased their Q2 2025 EPS estimates for Biogen in a research report issued on Thursday, July 24th. Zacks Research analyst S. Ganoria now expects that the biotechnology company will earn $3.83 per share for the quarter, down from their prior estimate of $4.09. The consensus estimate for Biogen's current full-year earnings is $15.83 per share. Zacks Research also issued estimates for Biogen's FY2025 earnings at $14.38 EPS.

Biogen (NASDAQ:BIIB - Get Free Report) last posted its quarterly earnings results on Thursday, May 1st. The biotechnology company reported $3.02 earnings per share for the quarter, missing analysts' consensus estimates of $3.26 by ($0.24). The business had revenue of $2.43 billion for the quarter, compared to the consensus estimate of $2.25 billion. Biogen had a return on equity of 14.03% and a net margin of 15.07%. The company's quarterly revenue was up 6.2% on a year-over-year basis. During the same period last year, the firm earned $3.67 earnings per share.

A number of other research firms also recently weighed in on BIIB. Mizuho dropped their price target on shares of Biogen from $207.00 to $169.00 and set an "outperform" rating for the company in a research note on Wednesday, May 7th. Royal Bank Of Canada set a $213.00 target price on shares of Biogen and gave the stock an "outperform" rating in a report on Wednesday, June 25th. HSBC lowered shares of Biogen from a "buy" rating to a "hold" rating and set a $118.00 target price on the stock. in a report on Monday, April 28th. Needham & Company LLC reiterated a "hold" rating on shares of Biogen in a report on Thursday, June 12th. Finally, HC Wainwright reiterated a "buy" rating and issued a $187.00 target price on shares of Biogen in a report on Thursday, June 26th. Twenty-one equities research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus price target of $186.37.

Biogen Trading Down 0.8%

Shares of BIIB traded down $1.07 on Friday, reaching $131.52. 976,978 shares of the company's stock were exchanged, compared to its average volume of 1,173,055. The company has a current ratio of 1.44, a quick ratio of 1.01 and a debt-to-equity ratio of 0.27. The stock has a market capitalization of $19.27 billion, a P/E ratio of 12.98, a price-to-earnings-growth ratio of 1.91 and a beta of 0.14. The business has a 50 day moving average price of $129.74 and a two-hundred day moving average price of $132.51. Biogen has a 12 month low of $110.04 and a 12 month high of $219.44.

Insider Buying and Selling

In other Biogen news, insider Rachid Izzar sold 2,223 shares of the stock in a transaction on Tuesday, July 8th. The shares were sold at an average price of $135.00, for a total value of $300,105.00. Following the completion of the sale, the insider owned 6,330 shares in the company, valued at $854,550. This trade represents a 25.99% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. 0.18% of the stock is currently owned by corporate insiders.

Institutional Trading of Biogen

Large investors have recently added to or reduced their stakes in the company. Integrated Quantitative Investments LLC acquired a new stake in Biogen in the fourth quarter valued at $407,000. Sumitomo Mitsui Trust Group Inc. lifted its stake in shares of Biogen by 6.5% during the 1st quarter. Sumitomo Mitsui Trust Group Inc. now owns 416,960 shares of the biotechnology company's stock worth $57,057,000 after buying an additional 25,464 shares during the last quarter. Asset Management One Co. Ltd. lifted its stake in shares of Biogen by 5.5% during the 1st quarter. Asset Management One Co. Ltd. now owns 61,420 shares of the biotechnology company's stock worth $8,405,000 after buying an additional 3,194 shares during the last quarter. APG Asset Management N.V. lifted its stake in shares of Biogen by 346.1% during the 4th quarter. APG Asset Management N.V. now owns 105,446 shares of the biotechnology company's stock worth $15,572,000 after buying an additional 81,811 shares during the last quarter. Finally, Assenagon Asset Management S.A. lifted its stake in shares of Biogen by 3.1% during the 1st quarter. Assenagon Asset Management S.A. now owns 44,796 shares of the biotechnology company's stock worth $6,130,000 after buying an additional 1,336 shares during the last quarter. Institutional investors and hedge funds own 87.93% of the company's stock.

About Biogen

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.